Last updated: April 23, 2026
What does CN116898874 cover and what does the claim set likely protect?
CN116898874 is a Chinese patent application with document status tied to publication under the CN116… family. Without the full published specification and claim text (claims, dependent claim chain, and scope-defining embodiments), a complete, accurate claim-by-claim scope analysis and a reliable patent-landscape map cannot be produced.
Scope and claim coverage: what can be determined from the record?
No claim set or claim construction details are available in the provided prompt. A scope assessment requires, at minimum, the full text of:
- Independent claims (scope-defining elements and product/process boundaries)
- Dependent claims (additional limitations that narrow or carve out variants)
- Claim formatting (Markush groups, compositional ranges, process steps)
- Key definitions in the specification (drug substance identity, salts/hydrates, polymorph IDs, dosage forms, method-of-treatment endpoints)
- Priority and filing data to correctly anchor family members and related filings
Can a China drug patent landscape be mapped for CN116898874?
A landscape requires:
- The patent’s exact publication number and legal status in China (granted vs pending, invalidation posture)
- The full family (WO/EP/US/JP filings mapped to CN equivalents)
- Cited prior art list from the CN publication (non-patent literature and patent documents)
- Listing of relevant Chinese patents for the same active ingredient, salts, polymorphs, formulations, and methods of treatment in the same therapeutic area
- Related “blocking” or “carve-out” documents (e.g., formulation patents that avoid the active substance claims, or polymorph-specific patents)
None of those inputs are present in the prompt.
Key risks to investors and R&D teams (based on missing but required claim facts)
Without the claims and family metadata, any landscape characterization would be speculative. In practice, decisions hinge on whether CN116898874 claims:
- The active pharmaceutical ingredient (API) identity vs only formulations
- A specific salt/hydrate/polymorph vs broader composition scope
- A method-of-treatment with defined clinical endpoints vs general therapeutic use
- Manufacturing steps with narrow process control vs a broad product-by-process claim
- Fixed dosing regimens vs “therapeutically effective amount” language
Each branch changes freedom-to-operate (FTO), launch timing, and litigation exposure.
Key takeaways
- A detailed scope and claim-by-claim analysis for CN116898874 cannot be completed from the provided information.
- A defensible China patent landscape for CN116898874 cannot be constructed without the published claim text, family members, cited prior art, and legal status.
FAQs
-
What is required to analyze a patent’s claim scope in China?
The full published claims (independent and dependent), the specification sections that define drug identity and ranges, and the family’s priority chain.
-
What typically drives freedom-to-operate in Chinese drug patents?
Whether the CN claims cover API identity, specific salt or polymorph forms, formulation composition, and whether method-of-treatment claims lock in dosing regimens or endpoints.
-
Why does family mapping matter for CN patents?
Family members often include different claim strategies (composition vs process vs use) that affect both validity and enforcement.
-
What inputs are essential for a patent landscape map?
Exact publication numbers, legal status, cited prior art, and the set of relevant CN filings for the same drug substance and therapeutic indication.
-
Can prior art be identified without the patent’s references section?
Not reliably; the landscape needs the CN publication’s cited documents and classification markers to avoid missing key earlier disclosures.
References
[1] No sources were provided in the prompt to cite.
